Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -1300.98% is 167% below its 4-year average of -486.62%, around the middle of its 4-year range (-2162.69%–-14.09%).
17.37% below its 12-month average of -1108.45%.
Reported quarterly return on assets; no daily interpolation. Q3 FY2025 (2026-03-31): -26.08%.
RETURN ON ASSETS (ROA)
-1300.98%
RETURN ON ASSETS (ROA) AVG TTM
-1108.45%
RETURN ON ASSETS (ROA) AVG 3Y
-604.75%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-17.37%
CURRENT VS 3Y AVG
-115.13%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 850 covered companies
CURRENT VS SECTOR MEDIAN
-3932.17%
vs the sector median at left
Lunai Bioworks Inc.
Market Cap
$5.21M
Return on Assets (ROA)
-1300.98%
TTM Avg
-1108.45%
3Y Avg
-604.75%
5Y Avg
N/A
Market Cap
$5.22M
Return on Assets (ROA)
-123.63%
TTM Avg
-110.43%
3Y Avg
-77.11%
5Y Avg
-65.55%
Market Cap
$5.20M
Return on Assets (ROA)
-30.94%
TTM Avg
-24.01%
3Y Avg
-19.50%
5Y Avg
-23.56%
Market Cap
$5.24M
Return on Assets (ROA)
-104.10%
TTM Avg
-116.11%
3Y Avg
-102.15%
5Y Avg
-84.67%
Market Cap
$5.29M
Return on Assets (ROA)
-106.49%
TTM Avg
-259.99%
3Y Avg
-586.63%
5Y Avg
-434.16%
Market Cap
$5.35M
Return on Assets (ROA)
-97.52%
TTM Avg
-106.09%
3Y Avg
-92.87%
5Y Avg
-84.52%
Market Cap
$5.03M
Return on Assets (ROA)
-71.72%
TTM Avg
-29.50%
3Y Avg
-8.92%
5Y Avg
-8.92%
Market Cap
$5.02M
Return on Assets (ROA)
-161.71%
TTM Avg
-175.21%
3Y Avg
-164.83%
5Y Avg
-138.13%
Market Cap
$5.02M
Return on Assets (ROA)
-98.17%
TTM Avg
-154.79%
3Y Avg
-120.06%
5Y Avg
-94.26%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lunai Bioworks Inc. (LNAI) | $5.21M | -1300.98% | -1108.45% | -604.75% | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | -123.63% | -110.43% | -77.11% | -65.55% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.20M | -30.94% | -24.01% | -19.50% | -23.56% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | -104.10% | -116.11% | -102.15% | -84.67% |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | -106.49% | -259.99% | -586.63% | -434.16% |
| Soligenix, Inc. (SNGX)vs › | $5.35M | -97.52% | -106.09% | -92.87% | -84.52% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.03M | -71.72% | -29.50% | -8.92% | -8.92% |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.02M | -161.71% | -175.21% | -164.83% | -138.13% |
| Imunon, Inc. (IMNN)vs › | $5.02M | -98.17% | -154.79% | -120.06% | -94.26% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.00M | -367.93% | -1046.51% | -534.79% | -427.52% |
ROA
-1301.0%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-06-30 | -2162.69% |
| 2024-06-30 | -54.21% |
| 2023-06-30 | -68.07% |
| 2022-06-30 | -134.03% |
| 2021-06-30 | -14.09% |
